H.I.G. Capital completes sale of BIOVECTRA

H.I.G. Capital announced the sale of its portfolio company, BIOVECTRA to Agilent Technologies for a purchase price of $925 million. Headquartered in Charlottetown, Prince Edward Island, Canada, BIOVECTRA has approximately 650 employees and eight facilities with over 270,000 square feet of facility space. The Company produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics H.I.G. acquired BIOVECTRA in November 2019 and successfully established the Company as an independent, standalone organization. H.I.G. supported the Company in strengthening the executive management team, successfully completing three major facility build-outs, and growing the sales pipeline significantly while shifting the Company’s business profile to focus more on commercial products. Due to these strategic initiatives, the Company achieved an industry-leading growth profile, resulting in an outstanding outcome for shareholders.